Shares of Roche Holding AG (OTCMKTS:RHHBY – Get Free Report) have earned a consensus recommendation of “Moderate Buy” from the twelve analysts that are presently covering the company, Marketbeat Ratings reports. Six research analysts have rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $60.00.
A number of brokerages have recently commented on RHHBY. HSBC restated a “hold” rating on shares of Roche in a research note on Thursday, September 10th. Zacks Research raised Roche from a “strong sell” rating to a “hold” rating in a report on Monday, August 24th. Morgan Stanley upgraded Roche from an “equal weight” rating to an “overweight” rating and set a $63.00 price objective on the stock in a research report on Friday, August 7th. Finally, Royal Bank Of Canada initiated coverage on shares of Roche in a research note on Tuesday, September 8th. They set an “outperform” rating on the stock.
Read Our Latest Stock Analysis on Roche
Institutional Inflows and Outflows
Key Stories Impacting Roche
Here are the key news stories impacting Roche this week:
- Positive Sentiment: Sefaxersen succeeds in a Phase 3 IgA nephropathy trial. Roche and partner Ionis Pharmaceuticals said the investigational RNA-targeted therapy met the primary endpoint and significantly reduced proteinuria, a key measure of kidney damage. The result could position sefaxersen as a potential treatment for the rare kidney disease and adds value to Roche’s partnered pipeline. Roche Reports Positive Phase 3 Data for Sefaxersen in IgA Nephropathy
- Positive Sentiment: Roche agreed to a potentially $2 billion drug-discovery partnership with Atavistik Bio. The collaboration will develop oral therapies for cardiovascular, kidney and metabolic diseases, broadening Roche’s pipeline and giving it access to Atavistik’s discovery platform. Most of the deal value is tied to future milestones, so the financial benefit is longer term rather than immediate. Roche Signs Drug-Discovery Deal With Atavistik Bio Worth Up to $2 Billion
- Positive Sentiment: Roche’s obesity program remains a potential growth catalyst. Recent Phase 2 data for enicepatide, an experimental GLP-1/GIP medicine, showed competitive weight loss and glucose control, supporting the company’s ambitions to challenge Novo Nordisk and Eli Lilly in the obesity market. Roche Latest Obesity Data Suggests Pharma Is in Line to Become Global GLP-1 Player
- Neutral Sentiment: Roche nominated former Takeda CEO Christoph Weber to its board, a governance and leadership update with limited immediate earnings impact. Brokerages continue to assign the stock a consensus “Moderate Buy” rating.
- Negative Sentiment: Sefaxersen’s positive result still requires longer-term validation. Interim data showed a meaningful reduction in proteinuria, but Roche reportedly needs approximately two years of evidence on kidney-function preservation. That uncertainty could delay approval, limit near-term commercial expectations and offset some of the initial optimism surrounding the trial. Roche Drops as Phase 3 Kidney Signal Needs Two-Year Proof
Roche Price Performance
Shares of RHHBY opened at $54.80 on Friday. The business’s 50-day moving average is $55.06 and its two-hundred day moving average is $52.38. Roche has a fifty-two week low of $39.50 and a fifty-two week high of $60.85. The company has a quick ratio of 1.12, a current ratio of 1.38 and a debt-to-equity ratio of 0.72.
About Roche
Roche Holding AG is a Switzerland-based healthcare company that develops and provides pharmaceutical products and diagnostic solutions. Founded in 1896 and headquartered in Basel, Roche operates through two complementary divisions: Pharmaceuticals and Diagnostics.
The Pharmaceuticals division focuses on medicines for oncology, immunology, neuroscience, ophthalmology, hematology and other therapeutic areas. Its portfolio includes treatments such as Ocrevus, Hemlibra, Perjeta, Tecentriq and Vabysmo.
Featured Stories
- Five stocks we like better than Roche
- Hims & Hers Slides Nearly 7% as Legal Pressure Adds to Its Growing List of Risks
- Paychex Plunges, Providing the Entry Investors Have Been Waiting For
- The Case for Buying High-Yield General Mills Just Strengthened
- SanDisk’s $1,800 Breakout Turns Memory Hardware Into a Profit Story
Receive News & Ratings for Roche Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roche and related companies with MarketBeat.com's FREE daily email newsletter.
